Add to ORKGEssential thrombocythaemia (ET) is a myeloproliferative neoplasm(MPN) characterised by megakaryocyte hyperplasia and thrombo-cytosis. From the genetic perspective, ET patients harbourmutations inJAK2(50–60%),CALR(15–30%) andMPL(1–5%) genes.This study was supported in part by grants from ISCIII and Spanish Ministry of Health, PI13/00557, PI13/00393, RD12/0036/0010, PT13/0010/0005, 2014SGR567 and the Xarxa de Banc de Tumors de Catalunya
Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloprolife...
Essential thrombocythemia (ET) is rare in children, and little or no information is available about ...
Essential thrombocythemia, as defined by the WHO in 2016, is a Philadelphia-negative chronic myelopr...
Essential thrombocythaemia (ET) is a myeloproliferative neoplasm(MPN) characterised by megakaryocyte...
Background: Lack of demonstrable mutations affecting driver genes JAK2, CALR or MPL within the spect...
Approximately 10% to 15% of patients with essential thrombocythemia (ET) lack the common driver muta...
11These authors contributed equally to this worklished a single-cell sequencing method that opens th...
International audienceMutations in signaling molecules of the cytokine receptor axis play a central ...
The myeloproliferative disorders (MPDs) are clonal haematological malignancies comprising three main...
Classical BCR-ABL-negative myeloproliferative neoplasms (MPN) include polycythaemia vera, essential ...
International audiencePhiladelphia-negative classical myeloproliferative neoplasms (MPN) are clonal ...
True essential thrombocythemia (ET), may carry one of the known driver mutations (JAK2, MPL and CALR...
Polycythemia vera (PV) and essential thrombocythemia (ET) are diseases driven by canonical mutations...
Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic diseases characterized by...
Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloprolife...
Essential thrombocythemia (ET) is rare in children, and little or no information is available about ...
Essential thrombocythemia, as defined by the WHO in 2016, is a Philadelphia-negative chronic myelopr...
Essential thrombocythaemia (ET) is a myeloproliferative neoplasm(MPN) characterised by megakaryocyte...
Background: Lack of demonstrable mutations affecting driver genes JAK2, CALR or MPL within the spect...
Approximately 10% to 15% of patients with essential thrombocythemia (ET) lack the common driver muta...
11These authors contributed equally to this worklished a single-cell sequencing method that opens th...
International audienceMutations in signaling molecules of the cytokine receptor axis play a central ...
The myeloproliferative disorders (MPDs) are clonal haematological malignancies comprising three main...
Classical BCR-ABL-negative myeloproliferative neoplasms (MPN) include polycythaemia vera, essential ...
International audiencePhiladelphia-negative classical myeloproliferative neoplasms (MPN) are clonal ...
True essential thrombocythemia (ET), may carry one of the known driver mutations (JAK2, MPL and CALR...
Polycythemia vera (PV) and essential thrombocythemia (ET) are diseases driven by canonical mutations...
Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic diseases characterized by...
Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloprolife...
Essential thrombocythemia (ET) is rare in children, and little or no information is available about ...
Essential thrombocythemia, as defined by the WHO in 2016, is a Philadelphia-negative chronic myelopr...